

Lessons Learnt by the National Patient Safety Agency

14th December 2007

Dr Helen Glenister
Deputy Chief Executive
NPSA



Overview

- Background to NPSA
- National Reporting and Learning System in England and Wales
- Using information to make change
- Approaches to Solutions Development
- Involvement of Patients



England and Wales

- No. Population: 53,728,800
- No. of Organisations in NHS: 429
- No. of consultations:
 - Over 1.5 million patients and their families are in contact with NHS services every day
- No. of Staff: 1.3 million people employed in NHS



NPSA: Background

- An organisation with a memory (2000)
- Building a safer NHS for patients (2001)
- Safety First: A report for patients, clinicians and healthcare managers (DH 2006)






The National Reporting Learning System

- All NHS organisations (acute, mental health and primary care) are connected
- Confidential reporting
- Incidents are mainly reported electronically and uploaded from Local Risk Management Systems 99%
- Direct Reporting

NRLS




Figure 1: The National Reporting and Learning System





Change of Direction



 Rapid reporting of Patient Safety incidents that involve serious patient harm and death within 36 hours of the report.




Purposes of the National Reporting and Learning System

- To identify similar incidents and learning to those reported through rapid reporting
- Follow-up of similar incidents
- Identify trends and patterns for priority action in the future
- Surveillance of incidents related to risk prevention strategies
- Evaluate and inform policy development



Number of patient safety incidents reported by quarter, November 2003 to June 2007




*Source: Data are based on date the incident was reported to the NRLS



Source of Notification to NRLS, by quarter July 2006 to June 2007


Source of Notification	2006				2007			
	Jul - Sep		Oct - Dec		Jan - Mar		Apr - Jun	
	No. of Incidents	%						
LRMS	200,178	99.0	185,620	98.5	217,752	98.5	239,657	98.8
Eform	1,940	1.0	2,538	1.3	2,685	1.2	2,118	0.9
Community Pharmacy	62	0.0	229	0.1	527	0.2	820	0.3
Total	202,180	100.0	188,387	100.0	220,964	100.0	242,595	100.0

Care setting of incident reports, July 2006 to June 2007 National Patient Safety Agency



Source: Data is based on date the reported incident occurred, using data as of 04 July 2007


Reported degree of harm to patients, July 2006 to June 2007 National Patient Safety Agency



Source: Data is based on date the reported incident occurred, using data as of 04 July 2007. Patient groups and incidents with a missing degree of harm are excluded.

Reported Incidents Type between July 2006 to June 2007







Using Reporting Systems to make change

- Initiatives to make patient care safer
- Initiatives to improve the quality of reporting and promote a safety culture



Initiatives to Make Care Safer



From reporting to learning

3 Sentember 2007

Risk of confusion between non-lipid and lipid formulations of injectable amphotericin

Please circulate this advice to all relevant staff

The National Patient Safely Agency (NPSA) is alerting all healthcare staff involved in the use of intervenues amphdericin of the potentially lethal results in non-lipid and lipid formulations of the drug are confused. These different formulations are used for the freatment of systemic fungal infections. The NPSA is aware of two recent deaths and a number of near misses reported to the National Reporting and Learning System (NRLS) and other similar includes infernationally. Further information on the Issues raised in this Rapid Response Report, for example the evidence base and a comparison of formulations/doces is at www.npca.nbs.u/health/alerts

Intravenous amphoterion is available in four different formulations, non-lipid deoxycholate complex (Fungizone[®]), and as lipid formulations (Abeloet[®], AmBisome[®], and Amphoolf[®]). The dosage recommendations for these preparations range from 1 – Smg/kg. Conflusion between the different formulations of amphoterion products can lead to:

- over or under dosing due to the different dose recommendations for each product;
- patients experiencing potentially lethal side effects or sub-therapeutic doses.

For IMMEDIATE ACTION by the NHS and the independent sector the deadline date for ACTION COMPLETE is 1 October 2007

- The Chief pharmacists, pharmaceutical advisers and heads of pharmacy and medicines management in healthcare organisations should ensure that medical, nursing and pharmacy staff involved in the prescribing, preparation, supply and administration of amphotericin are aware of the notential risks.
- Undertake an immediate risk assessment of amphotericin products and procedures in accordance with NPSA's Patient Safety Alert 20: Promoting safer use of Injectable medicines, and take action to reduce the risks.

Further information about risks and actions which can be taken to reduce these risks and details of NPSA's Patient Safety Alert 20 can be found at www.npsa.nhs.uk/heaith/alerts

The NPSA has informed

All acute sector and Primary Care NHS organisations, the MHRA, Pharmaceutical industry, independent Healthcare Advisory Services, Royal Colleges, Royal Pharmaceutical Society, Guild of Healthcare Pharmacists, NHS Pharmaceutical Aseptic Services Group.

Further NPSA action

We will conflue to monitor any incident reports involving intravenous amphotericin which are reported to the NRLS. For further information, contact Professor David Cousins on 020 7927 9356 or david Cousins@npes.ans.uk or email migroposa.nis.uk

DH Gateway number: 8726

- Raise Awareness
- Issued within two weeks
- Identifies immediate action
- System to track activity
- Deadline for completion



Initiatives to Make Care Safer







Solutions: preventing errors: a hierarchy NHS

Design out the potential for harm

Make incorrect actions correct

Make wrong actions more difficult

Make it easier to discover errors

Involvement of Patients



National Patient Safety Agency

- Understand the issues
- Part of the solution
- Produced health service and patient Briefing








Using systematic analysis and the 'observatory' approach to learn and respond

Monthly systematic analysis of deaths reported to the NRLS in 2005 (n = 1,804)

Of these – maybe or was considered directly attributable to a Patient Safety Incident (n = 576)

Reveals 3 main themes:

- 1. Diagnostic error (n = 86)
- 2. Deterioration not recognised or not acted upon (n = 66)
- 3. Resuscitation (n = 59)





Role of Qualitative Data in Reporting Systems


- Provides useful additional information for learning
- Provides case studies to illustrate points which front-line clinicians relate to
- Brings incidents and learning alive



Initiative to improve the quality and reporting and promote a safety culture

Quality Feedback Reports to Trusts

Figure 2: Incident rate per one hundred admissions



Source: patient safety incident reports successfully submitted to the NRLS where the incident occurred during the period 1 October 2006 to 31 March 2007



Sharing Information for NRLS to improve Patient Safety

- Regulator of Health Care (Healthcare Commission)
- Commissioners of Health Care
- Performance Management of Health Care



Summary

Lessons from NPSA:

- National Reporting and Learning System is important for making change
- Quality of data is a challenge
- Need new approaches to Solution Development
- Involvement of Patients important element to raise awareness to be part of the solutions